Landscape Search
Search by mechanism of action, indication, or therapeutic area to map the competitive landscape
GLP-1 landscape
Heart failure
Lipid lowering
Atopic dermatitis
Alzheimer's pipeline
GLP-1 Clinical Development Landscape
Phase 3
5 compounds
Oral Semaglutide (Rybelsus)
Novo Nordisk
Obesity
T2DM
NASH
Data readout imminent · NCT05035095
Orforglipron (LY3502970)
Eli Lilly
Obesity
T2DM
Recruitment complete · NCT05869903
Tirzepatide (Mounjaro)
Eli Lilly
Heart Failure
OSA
NASH
Enrolling patients · NCT06078800
Survodutide (BI 456906)
Boehringer Ingelheim
Obesity
NASH
Enrolling patients · NCT06161766
Pemvidutide (ALT-801)
Altimmune
Obesity
NASH
Recruiting · NCT06103045
Phase 2
7 compounds
Danuglipron (PF-06882961)
Pfizer
Obesity
T2DM
Enrolling (modified-release) · NCT06328504
Ecnoglutide (XW003)
Sciwind Biosciences
Obesity
Data readout imminent · NCT05813925
Maribardbart Cafraglutide (AMG 133)
Amgen
Obesity
Enrolling · NCT06047067
TERN-601
Terns Pharmaceuticals
Obesity
NASH
Recruiting · NCT06401824
RTTX-3008
Reata / Biogen
Obesity
CKD
Initiated · NCT06510338
INV-347
Inversago / Novo Nordisk
Obesity
Enrolling · NCT06289543
VK2735
Viking Therapeutics
Obesity
Enrolling · NCT06425783
Phase 1
4 compounds
NNC0487-0111
Novo Nordisk
Obesity
Recruiting · NCT06543901
ERX-1000
ERX Pharmaceuticals
Obesity
T2DM
Study initiated · NCT06601234
GMA-106
Gmax Biopharm
Obesity
Recruiting · NCT06187890
ZG-19018A
Suzhou Zelgen
Obesity
T2DM
First-in-human · NCT06711234
Preclinical
2 compounds
Undisclosed GLP-1/GIP/GCGR
AstraZeneca
ObesityCKD
IND-enabling
Oral GLP-1 Program
Structure Therapeutics
Obesity
Lead optimisation
Q1 2026
Q2 2026
Q3 2026
Q4 2026
H1 2027
H2 2027
● Oral Sema — Ph3 topline
● Ecnoglutide — ADA data
● Orforglipron — Ph3 interim
● MariCafra — Ph2 topline
● VK2735 — ENDO poster
● Survodutide — NASH readout
● INV-347 — Ph2 data
● Tirzepatide — HFpEF data
● Pemvidutide — Ph3 interim
● TERN — Funding round
● Danuglipron MR — Ph2b topline
● Oral Sema — FDA filing
● NNC0487 — Ph1 safety
● ERX-1000 — Ph1 PK data
Data Readout
Regulatory Filing
Conference
Launch/Approval
Financial
| Asset | Company | Phase | Molecule | Route | Indications | Status | Next Catalyst | Assessment |
|---|---|---|---|---|---|---|---|---|
| Oral Semaglutide | Novo Nordisk | Phase 3 | Small Mol. | Oral | Obesity, T2DM, NASH | Data imminent | Mar 2026 | |
| Orforglipron | Eli Lilly | Phase 3 | Small Mol. | Oral | Obesity, T2DM | Recruited | Q2 2026 | |
| Tirzepatide | Eli Lilly | Phase 3 | Peptide | Injectable | HF, OSA, NASH | Enrolling | H2 2026 | |
| Survodutide | Boehringer Ingelheim | Phase 3 | Peptide | Injectable | Obesity, NASH | Enrolling | Q3 2026 | |
| Pemvidutide | Altimmune | Phase 3 | Peptide | Injectable | Obesity, NASH | Recruiting | Q4 2026 | |
| Danuglipron | Pfizer | Phase 2 | Small Mol. | Oral | Obesity, T2DM | Enrolling (MR) | H1 2027 | |
| VK2735 | Viking Therapeutics | Phase 2 | Peptide | Inj. & Oral | Obesity | Enrolling | H1 2026 | |
| MariCafra (AMG 133) | Amgen | Phase 2 | Bispecific Ab | Injectable | Obesity | Enrolling | Q2 2026 | |
| Ecnoglutide | Sciwind | Phase 2 | Peptide | Injectable | Obesity | Data imminent | Q1 2026 | |
| TERN-601 | Terns Pharma | Phase 2 | Small Mol. | Oral | Obesity, NASH | Recruiting | H2 2026 | |
| INV-347 | Inversago / Novo | Phase 2 | Small Mol. | Oral | Obesity | Enrolling | Q3 2026 | |
| RTTX-3008 | Reata / Biogen | Phase 2 | Pep. Conj. | Injectable | Obesity, CKD | Initiated | 2027 | |
| NNC0487-0111 | Novo Nordisk | Phase 1 | Peptide | Oral | Obesity | Recruiting | 2027 | |
| ERX-1000 | ERX Pharma | Phase 1 | Small Mol. | Oral | Obesity, T2DM | Initiated | 2027 | |
| GMA-106 | Gmax Biopharm | Phase 1 | Peptide | Injectable | Obesity | Recruiting | H2 2027 | |
| ZG-19018A | Suzhou Zelgen | Phase 1 | Small Mol. | Oral | Obesity, T2DM | First-in-human | 2028 |